ArticleCureus2025
Impact of Anticoagulant and Antiplatelet Therapy on the National Optimal Lung Cancer Pathway (NOLCP).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study.JTO clinical and research reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains the leading cause of cancer-related mortality in the UK, with early diagnosis critical to improving survival. The National Optimal Lung Cancer Pathway (NOLCP) aims to streamline diagnosis and treatment, recently introducing a three-day direct-to-biopsy target for select patients. However, many lung cancer patients are on medications that increase the risk of bleeding (RoB), which may delay biopsy scheduling.
methodsA retrospective study was conducted at University Hospitals Plymouth NHS Trust over nine months, evaluating patients who underwent diagnostic procedures leading to a lung cancer diagnosis. Data were collected on referral times, diagnostic intervals, and RoB medication use. Statistical analysis assessed the impact of RoB medications and other factors on time to biopsy.
resultsOf 177 patients undergoing diagnostic procedures, 32 (18%) were on RoB medications, most commonly anticoagulants for atrial fibrillation. The median time from referral to biopsy was 13 days, with only five (15%) meeting the five-day target. While RoB medications did not significantly affect time from referral to biopsy, they did impact clinic-to-biopsy intervals (median 8 vs. 5 days; p=0.022). Only nine (28%) of RoB patients underwent biopsy within five days of clinic, versus 65 (50%) of others who had a final diagnosis of lung cancer. Delays were amplified in patients seen later in the week.
conclusionRoB medications were associated with meaningful delays from clinic to biopsy, challenging NOLCP's three-day biopsy target. Early identification and proactive management of these patients at triage, along with flexible procedural scheduling, are essential to reduce delays and improve diagnostic timelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.